GIP and type 2 diabetes mellitus: In a recent study involving individuals with T2D and MASLD, treatment with tirzepatide for 52 weeks resulted in greater reductions in liver fat and improvements in MASLD biomarkers compared with placebo.20 To date, no study has compared the effectiveness of GCGR/GLP-1RA and GIP/GLP-1RA for MASLD comprehensively.